Compound Detail
CHEMBL73451
MEQUITAZINE 🧪 Phase II
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
🧪 Phase II
Basic Information
| ChEMBL ID | CHEMBL73451 |
| Name | MEQUITAZINE |
| Phase | Phase II |
| Structure Type | MOL |
| InChI Key | HOKDBMAJZXIPGC-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
5
Targets
11
Activities
3
Assay Types
1
PK Parameters
20
Publications
5
Known Names
1
Indications
1
Mechanisms
Molecular Properties
322.5
MW (Da)
4.63
ALogP
3
HBA
0
HBD
6.5
PSA (Ų)
0.80
QED
0
Ro5 Violations
2
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| Chirality | Racemic |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Histamine H1 receptor antagonist | ANTAGONIST | Histamine H1 receptor | ✓ | ✓ |
Indications
Hypersensitivity
ATC Classification
R06AD07
mequitazine
Level 1: RESPIRATORY SYSTEM
Level 2: ANTIHISTAMINES FOR SYSTEMIC USE
Activity Summary
IC50 8 meas. best 5.26
Ki 2 meas. best 9.0
EC50 1 meas. best 5.1
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Histamine H1 receptor CHEMBL3943 | Ki | 9.0 | 8.5 | 1.0 | 2 |
| Unchecked CHEMBL612545 | IC50 | 5.26 | 5.12 | 5431.0 | 3 |
| SARS-CoV-2 CHEMBL4303835 | IC50 | 5.14 | 5.14 | 7280.0 | 1 |
| Unchecked CHEMBL612545 | EC50 | 5.1 | 5.1 | 7930.0 | 1 |
| Trypanothione reductase CHEMBL5131 | IC50 | 4.66 | 4.66 | 21800.0 | 1 |
| Trypanothione reductase CHEMBL5154 | IC50 | 4.26 | 4.26 | 54300.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| CL | 34.0 | mL.min-1.g-1 | Homo sapiens |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| - | 10.6019/CHEMBL4651402 | SARS-CoV-2 | 4 |
| 7650688 | 10.1021/jm00017a019 | Histamine H1 receptor | 3 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 2A | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Glucocorticoid receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Peroxisome proliferator-activated receptor gamma | 2 |
| - | 10.6019/CHEMBL4808148 | Histone deacetylase 6 | 2 |
| - | 10.6019/CHEMBL4651402 | Vero C1008 | 2 |
| - | 10.6019/CHEMBL4495565 | SARS-CoV-2 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Estrogen receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Nuclear receptor subfamily 1 group I member 2 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Gamma-aminobutyric acid receptor subunit alpha-1/alpha-2/beta-2/gamma-2 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | D(1A) dopamine receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-2A adrenergic receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Progesterone receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Muscarinic acetylcholine receptor M2 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Cannabinoid receptor 1 | 2 |
| 19296695 | 10.1021/jm801306g | Trypanothione reductase | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-1A adrenergic receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 2B | 2 |
| - | 10.1101/2020.03.20.999730 | SARS-CoV-2 | 1 |
Data from ChEMBL 36 via Core Engine